Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 17, 2023--

Related Keywords

United States ,Japan ,Canada ,China ,Peter Dannenbaum ,Elizabeth Rhee ,Steven Graziano ,Julie Cunningham ,Deb Wambold ,European Commission ,European Medicines Agency ,Exchange Commission ,Linkedin ,Merck Research Laboratories ,Instagram ,Youtube ,Statement Of Merck Co Inc ,Committee For Medicinal Products Human Use ,European Union ,Drug Administration ,Merck Co Inc ,Aicuris Gmbh Co ,Twitter ,Facebook ,Medicinal Products ,Human Use ,Merck Research ,Safety Information ,Prescribing Information ,Aicuris Gmbh ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Medication Guide ,Media Contacts ,Business Wire ,Region ,